Kevin Bitterman - 18 Jun 2026 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Reporting relationship: Director
Issuer ticker: IRON
Reported as of: 18 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Jun 2026, 16:56:52 UTC
Prior SEC filing: 18 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Ommer Chohan, Attorney-in-Fact

Key filing fact

Kevin Bitterman filed Form 4 for Disc Medicine, Inc. (IRON) on 23 Jun 2026.

Key facts

This page summarizes Kevin Bitterman's Form 4 filing for Disc Medicine, Inc. (IRON).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 23 Jun 2026, 16:56.

Change

Previous filing in this sequence was filed on 18 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001591747 Primary reporting owner

Bitterman Kevin

Relationship: Director
Address: C/O DISC MEDICINE, INC., 321 ARSENAL STREET, SUITE 101, WATERTOWN
Signature: /s/ Ommer Chohan, Attorney-in-Fact
Signature date: 23 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IRON transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +6,212
Change %
Price: $0.000000^*
Shares after: 6,212
Date: 18 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 6,212
Exercise price: $70.79
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

Footnote F2

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.